Lucid Diagnostics is a commercial-stage cancer prevention company that develops diagnostic tools to detect esophageal precancer in patients with gastroesophageal reflux disease at risk of esophageal adenocarcinoma, a highly lethal cancer. The company offers two core products: EsoGuard, a DNA methylation assay that detects Barrett's esophagus precancer with high sensitivity and specificity, and EsoCheck, a noninvasive swallowable balloon device for sampling esophageal cells. Lucid generates revenue through multiple channels including its own test centers, satellite testing locations in physician offices, partnerships with health systems, employer contracts, and direct-to-consumer telemedicine, with reimbursement from Medicare, commercial insurance, and government programs.